Tracers / [68Ga]Ga-NODAGA-exendin-4
[68Ga]Ga-NODAGA-exendin-4
Also written as [68Ga]Ga-NODAGA-Exendin-4; [Ga-68]Ga-NODAGA-Exendin-4; Exendin-4; Ga-68 Exendin-4; Ga-68 NODAGA-exendin-4; NODAGA-exendin-4
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 23
What it is
- Compound class
- Radiolabelled GLP-1-receptor agonist peptide (exendin-4 analogue, NODAGA-conjugated)
- Target / mechanism
- Glucagon-like peptide-1 receptor (GLP-1R), markedly overexpressed in benign insulinomas PMID 36507990
- Clinical application
- Localisation of occult insulinomas via GLP-1-receptor imaging PMID 36507990
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | 45 ± 2.4% | 96.31% | NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 35056858 2022 Molecules Scintomics GRP® module, Fürstenfeldbruck, Germany — The mean radiochemical yield was 45 ± 2.4% in all the three validation batches of [68Ga]Ga-NODAGA-exendin-4. |
| miniAllinOne Trasis | vendor cassette | SPE | 67% | 97% | NODAGA[40Lys]-Exendin-4 piCHEM, Raaba-Grambach, Austria | 42223859 2026 EJNMMI Radiopharm Chem automated on the miniAllinOne synthesizer — a radiochemical yield of 67% |
| miniAllinOne Trasis | vendor cassette | SPE | 66 to 67% n.d.c.; 85 to 87% d.c. yes | ≥95% | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — confirming that the synthesis proceeded efficiently and provided high radiochemical yields (66 to 67% n.d.c. ; 85 to 87% d.c.). |
| miniAllinOne Trasis | vendor cassette | SPE | RCY = 60–65% n.d.c. and 76–82% d.c. yes | ≥95% | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — the measured residual activities and the calculated yields demonstrated the transferability of the automated radiosynthesis regardless of the generator used (RCY = 60–65% n.d.c. and 76–82% d.c.) |
| miniAllinOne Trasis | vendor cassette | SPE | 71–73% n.d.c. no | ≥95% | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — the addition of this protective agent enabled highest ever reported non-decay-corrected synthesis yields of 71–73%. |
| — | — | — | — | — | — | 42618557 2026 Cell Death Dis |
| miniAllinOne Trasis | vendor cassette | SPE | 66 to 67% n.d.c.; 85 to 87% d.c. yes | ≥95% | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — confirming that the synthesis proceeded efficiently and provided high radiochemical yields (66 to 67% n.d.c. ; 85 to 87% d.c.) |
| miniAllinOne Trasis | vendor cassette | SPE | 60–65% n.d.c. and 76–82% d.c. yes | ≥95% | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — the calculated yields demonstrated the transferability of the automated radiosynthesis regardless of the generator used (RCY = 60–65% n.d.c. and 76–82% d.c.) |
| miniAllinOne Trasis | vendor cassette | SPE | 71–73% no | — | Lys40-NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 42380410 2026 EJNMMI Radiopharm Chem All radiosyntheses were carried out on the miniAllinOne synthesiser (operated by the Supervision software, Fig. 2) — the addition of this protective agent enabled highest ever reported non-decay-corrected synthesis yields of 71–73% |
| — | — | — | — | — | — | 42314903 2026 Mol Metab |
| — | — | — | — | — | — | 42226100 2026 Cell Mol Biol Lett |
| miniAllinOne Trasis | vendor cassette | SPE | 67% | 97% | NODAGA-Exendin(40Lys)-4 piCHEM, Raaba-Grambach, Austria | 42223859 2026 EJNMMI Radiopharm Chem automated on the miniAllinOne synthesizer — with a mean radiochemical purity of 97% and a radiochemical yield of 67% |
| — | — | — | — | — | — | 41818251 2026 PLoS One |
| — | — | — | — | — | — | 41555052 2026 Diabetologia |
| — | — | — | — | — | — | 41385561 2026 Am J Physiol Endocrinol Metab |
| — | — | — | — | — | NODAGA-Exendin-4 | 40980831 2025 Endocrinol Diabetes Metab Case Rep |
| — | — | — | — | — | — | 40809148 2024 Front Syst Biol |
| — | — | — | — | — | — | 40447542 2025 Semin Nucl Med |
| Manual synthesis | — | SPE | — | >95% | NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 37265006 2023 Mol Pharm labeled with 68Ga by adding 2.5 M HEPES |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | NODAGA-exendin-4 piCHEM, Raaba-Grambach, Austria | 35889351 2022 Molecules the automated synthesis module Scintomics GRPTM (Scintomics GmbH, Fürstenfeldbruck, Germany) |
| — | — | SPE | 23.53 ± 2.4% | 91.69% | [Lys40,Nle14(Ahx-NODAGA)NH2]exendin-4 | 33687908 2022 Curr Radiopharm eluted with 0.1M HCl on an automated synthesis module (Scintomics GRP®) — getting the best radiochemical yield (23.53 ± 2.4%) |
| — | — | — | — | — | — | 42134453 2026 Metabolism |
| — | — | — | — | — | — | 41005352 2025 Nuklearmedizin |
Need this precursor?We can point you to suppliers for [68Ga]Ga-NODAGA-exendin-4, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-NODAGA-exendin-4.
Get in touchNotes
Added from reverse module search (stage 6); 3 article(s) with Ga-68.